Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies

Table 1

Anticancer chemotherapy-related severe cutaneous adverse drug reactions from the English literature (year: 1950–2017).

Drug class	Drug	Pharmacology	References	Total (n)	Mortality	SJS	SJS/TEN	TEN
Alkylating agents	Treosulfan	Alkysufonates	[6]	1	1	0	0	1
	Chlorambucil	Mustard gas derivatives	[7, 8]	2	0	0	0	2
	Mechlorethamine (topical)	Nitrogen mustard	[9]	1	0	1	0	0
	Temozolomide	Hydrazines and triazines	[10]	1	0	0	1	0
	Procarbazine	Hydrazines and triazines	[11–13]	3	0	0	0	3
Plant alkaloids	Paclitaxel	Taxanes	[14]	1	0	1	0	0
	Docetaxel	Taxanes	[15–19]	5	2	3	0	2
	Etoposide	Podophyllotoxins	[20]	1	0	1	0	0
Anthracyclines	Doxorubicin		[21]	1	1	0	0	1
Antimetabolites	Methotrexate	Folic acid antagonists	[22–26]	5	2	2	0	3
	Cytarabine	Pyrimidine antagonist	[27, 28]	2	2	0	0	2
	Fludarabine	Adenosine deaminase inhibitor	[29]	1	1	1	0	0
	Gemcitabine	Pyrimidine antagonist	[30–32]	3	0	2	1	0
	Capecitabine	Pyrimidine antagonist	[33]	1	0	1	0	0
	Cladribine	Purine antagonist	[34, 35]	2	NA	1	0	1
	6-Mercaptopurine	Purine antagonist	[36]	1	NA	0	0	1
	TS-1 (tegafur-gimeracil-oteracil potassium)		[37, 38]	2	0	1	0	1
	Pemetrexed	Multitarget antifolate	[39, 40]	2	0	0	0	2
Antitumor antibiotics	Bleomycin		[41, 42]	2	1	0	0	2
	Peplomycin		[43]	1	0	1	0	0
	Mithramycin		[44, 45]	2	0	0	0	2
Miscellaneous	Lenalidomide		[46–48]	14	2	12	1	1
	Thalidomide		[49–53]	5	1	1	0	4
	Asparaginase		[54]	1	0	0	0	1
			Total	60	13	28	3	29

NA: not available.